WaveMan
WaveMan · Company
TYRA · Tyra Biosciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TYRA Tyra Biosciences (TYRA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001863127
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
103
13F, latest reported quarter

What the filings say about TYRA

Insiders, 180 days
+$20.0K net bought
1 buyer

Tyra Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Tyra Biosciences, Inc. insiders bought a net $20.0K of stock across 149 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Verjee Rehan
Director
BUY
2026-09-11 SECtraded 2026-09-09
971.8943
$20.0K
-18.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 971 shares held after it.
  • No other insider bought within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Verjee Rehan bought about $20.0K of TYRA on Sep 9, 2026, the largest insider purchase at the company since 2025; 103 funds added in the latest 13F quarter.
KAPLAN GILLA
Director
SELL
2026-03-27 SECtraded 2026-03-25
14,295
$528.5K
-41.0%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 18, 2025.
  • The trade is 50.6% of the 28,231 shares held after it.
  • No other insider sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KAPLAN GILLA sold about $528.5K of TYRA on Mar 25, 2026; 103 funds added in the latest 13F quarter.
Bensen Daniel
Chief Discovery Officer
SELL
2026-02-13 SECtraded 2026-02-12
2,128
$67.0K
-29.9%
Context
  • 53 earlier Form 4 trades (code P or S) here by this insider (53 sales), the last on Jan 12, 2026.
  • The trade is 1.4% of the 152,853 shares held after it.
  • No other insider sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Discovery Officer Bensen Daniel sold about $67.0K of TYRA on Feb 12, 2026; 103 funds added in the latest 13F quarter.
Bensen Daniel
Chief Discovery Officer
SELL
2026-02-13 SECtraded 2026-02-12
5,872
$195.9K
-29.9%
Context
  • 53 earlier Form 4 trades (code P or S) here by this insider (53 sales), the last on Jan 12, 2026.
  • The trade is 4.0% of the 146,981 shares held after it.
  • No other insider sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Discovery Officer Bensen Daniel sold about $195.9K of TYRA on Feb 12, 2026; 103 funds added in the latest 13F quarter.
Bensen Daniel
Chief Discovery Officer
SELL
2026-01-20 SECtraded 2026-01-12
6,983
$198.6K
-30.6%
Context
  • 51 earlier Form 4 trades (code P or S) here by this insider (51 sales), the last on Dec 12, 2025.
  • The trade is 4.5% of the 155,998 shares held after it.
  • 1 other insider sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Discovery Officer Bensen Daniel sold about $198.6K of TYRA on Jan 12, 2026; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.
149 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 144 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$20.0K over 180 days
+$20.0K over 90 days
more than 69% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
103 funds bought in last quarter
more than 70% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
27.2% of the float short (float per yahoo 2026-10-26) · 8.8 days to cover · settled 2026-09-30
more than 87% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TYRA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+46.0%12M
+0%+61%+122%+183%2025-102025-122026-022026-042026-062026-082026-10 2025-11-21 · MORE ROBERT J sold $5.0M2025-11-14 · Bensen Daniel sold $1.8M2025-11-18 · Bensen Daniel sold $1.2M2025-11-19 · Bensen Daniel sold $815.3K2026-03-25 · KAPLAN GILLA sold $528.5K2025-11-17 · Bensen Daniel sold $299.2K2025-12-19 · MORE ROBERT J sold $250.0K2026-01-12 · Bensen Daniel sold $198.6K2026-02-12 · Bensen Daniel sold $195.9K2025-12-12 · Bensen Daniel sold $181.1K2026-02-12 · Bensen Daniel sold $67.0K2026-01-12 · Bensen Daniel sold $29.6K2025-11-17 · Bensen Daniel sold $25.6K2026-09-09 · Verjee Rehan bought $20.0K2025-11-13 · Bensen Daniel sold $17.8K2026-06-26 · NEXTECH VI ONCOLOGY SCSP filed to sell $9.5M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TYRA: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
12,198,625 sh
$389.6M
FMR LLC
8,920,513 sh
$284.9M
Jupiter Topco LLC
4,352,448 sh
$139.2M
Alta Partners Management Company, L.P.
3,823,425 sh
$122.1M
Nextech Invest Ltd.
3,553,585 sh
$113.5M

Congress trades in TYRA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TYRA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
NEXTECH VI ONCOLOGY SCSP
Filed 2026-06-26
$9.5M

TYRA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$1.9M position · as of 2026-05-31
1.1%
Virtus Biotech Clinical Trials Etf
$367.1K position · as of 2026-07-31
0.8%
Lord Abbett Micro-Cap Growth Fund
$1.7M position · as of 2026-07-31
0.8%
Fidelity Advisor Biotechnology Fund
$11.3M position · as of 2026-07-31
0.5%
PGIM Jennison Health Sciences Fund
$6.1M position · as of 2026-05-29
0.4%
NORTH SQUARE DYNAMIC SMALL CAP FUND
$3.3M position · as of 2026-05-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 7 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
3 active
3
Phase 2
3 active
1
Multi-phase
1 active
What changed recently
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activatin
2026-10-15 · Completion moved 2026-09 → 2027-03
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $20.0K bought by insiders over 180 days, 103 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TYRA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$109.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-45.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-42.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-48.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-9.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$132.8M-$104.2M-$79.9M-$58.9M
Net income-$119.9M-$86.5M-$69.1M-$55.3M
EPS (diluted)-2.01-1.51-1.62-1.32
Operating cash flow-$95.1M-$69.8M-$50.1M-$50.3M
Cash$77.4M$92.0M$58.0M$251.2M
SEC XBRL, fiscal years, as known on 2026-10-27

TYRA Stock Sonar score 4/7 axes

Find similar shapesCompare

TYRA ranks highest on institutional and government (70th percentile) and insider conviction (62nd), and lowest on risk and compliance (6th), among Pharma & Biotech peers.

Profitability
54
Inputs
  • Return on equity-45.3% · 58 pct, sector of 545
  • Return on assets-42.2% · 50 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-48.2% · 53 pct, sector of 576
Insider conviction
62
Inputs
  • Net Form 4 buying (codes P and S), 180d$20K · 67 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
70
Inputs
  • Funds adding, latest quarter103 · 70 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
6
Inputs
  • Short interest, % of float+27.2% · 6 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TYRA filings, in plain words

Are Tyra Biosciences insiders buying or selling TYRA?

In the 180 days to 2026-10-27, Tyra Biosciences insiders were net buyers, a net $20.0K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-27, Tyra Biosciences insiders were net buyers of TYRA, a net $20.0K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies